An announcement from Shanghai Pharmaceuticals Holding Co.,Ltd. (SH: 601607) reveals that its subsidiary, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd., has recently obtained a Drug Registration Certificate from the National Medical Products Administration.
The certificate, numbered 2026S02303, grants approval for the production of Vigabatrin Oral Solution Powder.
This medication is indicated for the treatment of infantile spasms.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments